BioSpace News Archive

Nacuity Pharmaceuticals, Inc. announced the appointment of Russell Kelley, Ph.D., MBA, to its board of directors.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug LX9211, a novel, highly selective inhibitor of adaptor-associated kinase 1 (AAK1), will be presented during a podium presentation at the 16th Annual Pain Therapeutics Summit in Washington, D.C.

PointClickCare Technologies today announced a strategic collaboration with Pfizer Inc. to provide real world insights into the population at high risk of age-related disorders, which is aligned with PointClickCare’s mission to protect and support the senior population.

The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).

Galecto, Inc. announced its operating and financial results for the quarter ended September 30, 2022.

Kardium Inc. announces the successful first-in-human study of its next generation Globe® Pulsed Field System to treat atrial fibrillation (AF) using pulsed field ablation (PFA) therapy.

Codetta® Biosciences announced today that the North Carolina Collaboratory has awarded Codetta and North Carolina Central University (NCCU) a $2 million research and development grant.

Unravel Biosciences, Inc. today announced a partnership with Spanios (“Spanios”), a precision oncology company facilitating effective treatments for patients with rare and other solid cancers.

NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced that enrollment has commenced in two large, multicenter double-blind trials of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD).

Vetigenics, an animal health biotechnology company, announced a second discovery collaboration with a major animal health pharmaceutical company for use of the VETIGENICS CANIBODY™ Platform.